ADVANCED SOLID TUMOR
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability,
and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors (Hutchison)
Phase I
The purpose of this study is to evaluate the safety, tolerability, and
pharmacokinetics of fruquintinib in patients with advanced solid tumors.
Multiple doses fruquintinib will be used to investigate the metabolite
profile of fruquintinib in the plasma of patients with advanced solid tumors.
Treatment agent: Fruquintinib
PI:
Thomas Stanton, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03251378